Clinical Trial Update: A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating extended-release niacin/laropiprant, laropiprant, ER niacin, and placebo on urinary prostanoid metabolites in adults with high choleste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Extended Release Niacin/Laropiprant (niacin/laropiprant)
• Extended-release Niacin (Niacin (extended-release))
• Laropiprant (laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED | Results posted: 2008-11-27